MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

Search

Evotec AG

Închisă

SectorFinanțe

7.33 0.27

Rezumat

Modificarea prețului

24h

Curent

Minim

7.12

Maxim

7.42

Indicatori cheie

By Trading Economics

Venit

-1.2M

-41M

Vânzări

36M

221M

Marjă de profit

-18.46

Angajați

4,740

EBITDA

58M

-45M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+39.37% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.1B

Deschiderea anterioară

7.06

Închiderea anterioară

7.33

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Evotec AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 iun. 2024, 13:17 UTC

Market Talk

Evotec's Profit Outlook Looks Gloomy -- Market Talk

Comparație

Modificare preț

Evotec AG Așteptări

Obiectiv de preț

By TipRanks

39.37% sus

Prognoză pe 12 luni

Medie 10.23 EUR  39.37%

Maxim 12.1 EUR

Minim 7 EUR

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEvotec AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.818 / 7.348Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Evotec AG

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.